• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Ridgetech Inc.

    12/16/25 5:01:01 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RDGT alert in real time by email
    6-K 1 ea0269917-6k_ridgetech.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-40724

     

     

     

    RIDGETECH, INC.
    (Translation of registrant’s name into English)

     

     

     

    5th Floor, Building 6, No. 100, 18th Street, Baiyang Sub-district Qiantang District
    Hangzhou City, Zhejiang Province, People’s Republic of China, 310008
    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    This report is incorporated by reference in our registration statements on Form F-3 (No. 333-291941 and No. 333-269182) and S-8 (No. 333-264505, No. 333-268809 and No. 333-277849), and shall be deemed to be a part thereof from the date on which this report is furnished to the Securities and Exchange Commission (the “SEC”), to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Submission of Matters to a Vote of Security Holders.

     

    On December 12, 2025, Ridgetech, Inc., a Cayman Islands exempted company (the “Company”) held its annual general meeting of shareholders for discussion and approval of a series of proposals as described in the Company’s proxy statement filed with the SEC on November 12, 2025 (the “Proxy Statement”). A quorum was present at the meeting as required by the Fourth Amended and Restated Memorandum and Articles of Association of the Company. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

    1.A proposal to approve by ordinary resolution of the election of each of the four following director nominees: Mr. Lingtao Kong, Ms. Caroline Wang, Mr. Jiangliang He and Dr. Genghua Gu to serve until the next annual meeting or until their successors are duly elected and qualified (the “Director Election Proposal”).

     

    Director’s Name   For   Withheld
    Lingtao Kong   4,284,363   22,509
    Caroline Wang   4,284,418   22,454
    Jiangliang He   4,284,416   22,456
    Genghua Gu   4,284,362   22,510

     

    1

     

     

    2. A proposal to ratify by ordinary resolution the appointment of YCM CPA, Inc. as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026 (the “Independent Accountants Ratification Proposal”).

     

    For   Against   Abstain
    4,286,523   20,492   61

     

    3.A proposal to approve by ordinary resolution the board of directors (the “Board”) to effect a consolidation of the Company’s authorized and issued ordinary shares, at a ratio of up to one-for-two hundred (1:200) (the “Consolidation of Ordinary Shares”), on a date to be determined by the Board but no later than the next annual general meeting of the shareholders of the Company, with the exact ratio to be set at a whole number within this range, as determined by the Board in its sole discretion (the “Approved Consolidation Ratio”), as further set forth in the Proxy Statement (the “Ordinary Share Consolidation Proposal”).

     

    For   Against   Abstain
    4,284,402   22,241   229

     

    4.A proposal to approve by special resolution, subject to the shareholder approval of the Ordinary Share Consolidation Proposal and the Board having effected the Consolidation of Ordinary Shares as authorized by the Ordinary Share Consolidation Proposal, that the Fifth Amended and Restated Memorandum and Articles of Association of the Company, a copy of which is attached to the Proxy Statement as Annex A, subject to adjustment solely in respect of the final Approved Consolidation Ratio, be adopted in substitution for, and to the exclusion of, the existing Fourth Amended and Restated Memorandum and Articles of Association of the Company to reflect the Consolidation of Ordinary Shares (the “Articles Restatement Proposal”).

     

    For   Against   Abstain
    4,283,572   23,271   29

     

    5.A proposal to approve by ordinary resolution the Fourth Amended and Restated 2010 Equity Incentive Plan, as attached to the Proxy Statement as Annex B (the “Equity Incentive Plan Proposal”).

     

    For   Against   Abstain
    4,283,568   23,275   29

     

    Pursuant to the foregoing votes, the election of each of the director nominees under the Director Election Proposal and the approval of each of the Independent Accountants Ratification Proposal, the Ordinary Share Consolidation Proposal, the Articles Restatement Proposal and the Equity Incentive Plan Proposal were approved in all respects.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: December 16, 2025 RIDGETECH, INC.
       
      By: /s/ Ming Zhao
      Name: Ming Zhao
      Title: Interim Chief Executive Officer and Chief Financial Officer

     

    3

     

     

    Get the next $RDGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RDGT
    SEC Filings

    View All

    SEC Form 424B5 filed by Ridgetech Inc.

    424B5 - Ridgetech Inc. (0001856084) (Filer)

    12/30/25 8:00:13 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    12/30/25 7:45:05 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    12/16/25 5:01:01 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    Financials

    Live finance-specific insights

    View All

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples